Introduction
cancers, intrahepatic cholangiocarcinoma, toxicity, Biliary tract cancer, cancers of the gallbladder, intrahepatic or extrahepatic cholangiocarcinoma
NEOPLASMS, CANCERS, INTRAHEPATIC CHOLANGIOCARCINOMA
Biliary tract cancer (BTC) comprises heterogenous neoplasms derived from epithelial cells in the biliary system including either intrahepatic or extrahepatic cholangiocarcinoma and cancers of the gallbladder and ampulla of Vater. Although BTC accounts for 3% of all adult cancers, its incidence has been increasing worldwide, primarily due to a rise in intrahepatic cholangiocarcinoma [A combination therapy of gemcitabine and cisplatin (GC) is a current standard of care for advanced BTC because it provides longer survival without any substantial toxicity as compared with gemcitabine alone [Recently, a survival benefit of FOLFOX (fluorouracil, leucovorin, and oxaliplatin) has been shown in patients with BTC refractory to the first-line gemcitabine-based chemotherapy [